ALKS
Alkermes Plc
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 2.58B; Volume: 112.26K; AvgVol 3m: 1.34M; Beta: 1.29;
Cost estimate:
P/E: –; EPS: -0.80; EPS growth quarter/prev quarter: 30.80%;
EPS growth this year: -39.40%; EPS growth past 5 years: -43.30%;
EPS ttm: -0.80;
P/S: 2.25; P/B: 2.39; P/Cashflow: 4.91; P/FCF: ;
Sales: 1.16B; Sales growth quarter/prev quarter: -11.60%; Sales growth past 5 years: 13.60%;
Profitability:
Gross Margin: 84.40%; Profit Margin: -10.90%; Operating Margin: -11.60%;
ROA – return on assets: -7.00%; ROE – return on equity: -11.80%; LT Debt/Equity: 0.26; Total Debt/Equity: 0.26;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.70%; Insider Transactions:-15.63%;
Institutional Ownership: 96.66%; Institutional Transactions: 2.15%;
Data update: 07.10.2020.